ArticleBMC pulmonary medicine2025
Impact of pressure support ventilation duration after a spontaneous breathing trial on reintubation rates in critically ill subjects: a retrospective study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo investigate the effect of different durations of pressure support ventilation (PSV) after a spontaneous breathing trial (SBT) on 48-hour reintubation rates in critically ill subjects.
methodsThis single-center retrospective cohort study included adult subjects who received mechanical ventilation for over 48 h, successfully completed SBT, and were scheduled for extubation in the intensive care unit of a tertiary hospital between January and December 2023. Subjects were divided into three groups based on PSV duration after SBT: direct extubation (DE, ≤ 30 min), short-term PSV (SP, 30 min-3 h), and long-term PSV (LP, 3-12 h). The primary outcome was the 48-hour reintubation rate. The secondary outcomes included intensive care unit length of stay and 28-day mortality.
resultsA total of 982 subjects were included (638, 235, and 109 in the DE, SP, and LP groups, respectively). The 48-hour reintubation rates were 18.34%, 14.04%, and 16.51% in the DE, SP, and LP groups, respectively (P = 0.298). Multivariate logistic regression showed no significant difference in reintubation risk for SP (OR = 0.73, P = 0.141) and LP groups (OR = 0.88, P = 0.643) compared with the DE group. Age (OR = 1.18, P = 0.003) and APACHE II score (OR = 1.07, P < 0.001) were identified as independent risk factors for reintubation. The median intensive care unit length of stay was 16 days in the DE group, 18 days in the SP group, and 19 days in the LP group (P = 0.033). The 28-day mortality did not differ significantly among groups (12.85%, 11.91%, and 14.68%, respectively; P = 0.690).
conclusionsPSV duration after SBT did not significantly affect reintubation rates in the overall population. While short-term PSV showed potential benefits in specific subgroups, particularly COPD patients, direct extubation after successful SBT appears safe for most patients and may reduce ICU length of stay. These findings suggest that extubation strategies should be individualized based on patient characteristics rather than applying extended PSV periods universally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.